1. Home
  2. IBRX vs PFS Comparison

IBRX vs PFS Comparison

Compare IBRX & PFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • PFS
  • Stock Information
  • Founded
  • IBRX 2014
  • PFS 1839
  • Country
  • IBRX United States
  • PFS United States
  • Employees
  • IBRX N/A
  • PFS N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • PFS Savings Institutions
  • Sector
  • IBRX Health Care
  • PFS Finance
  • Exchange
  • IBRX Nasdaq
  • PFS Nasdaq
  • Market Cap
  • IBRX 2.3B
  • PFS 2.5B
  • IPO Year
  • IBRX N/A
  • PFS N/A
  • Fundamental
  • Price
  • IBRX $2.26
  • PFS $18.42
  • Analyst Decision
  • IBRX Strong Buy
  • PFS Strong Buy
  • Analyst Count
  • IBRX 6
  • PFS 5
  • Target Price
  • IBRX $9.83
  • PFS $23.00
  • AVG Volume (30 Days)
  • IBRX 9.4M
  • PFS 579.9K
  • Earning Date
  • IBRX 11-10-2025
  • PFS 10-29-2025
  • Dividend Yield
  • IBRX N/A
  • PFS 5.21%
  • EPS Growth
  • IBRX N/A
  • PFS 99.22
  • EPS
  • IBRX N/A
  • PFS 1.96
  • Revenue
  • IBRX $56,600,000.00
  • PFS $836,917,000.00
  • Revenue This Year
  • IBRX $629.94
  • PFS $26.69
  • Revenue Next Year
  • IBRX $109.91
  • PFS $11.38
  • P/E Ratio
  • IBRX N/A
  • PFS $9.40
  • Revenue Growth
  • IBRX 4227.22
  • PFS 59.19
  • 52 Week Low
  • IBRX $1.83
  • PFS $14.34
  • 52 Week High
  • IBRX $5.88
  • PFS $22.24
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 39.09
  • PFS 42.74
  • Support Level
  • IBRX $2.30
  • PFS $18.08
  • Resistance Level
  • IBRX $2.67
  • PFS $19.01
  • Average True Range (ATR)
  • IBRX 0.12
  • PFS 0.52
  • MACD
  • IBRX -0.02
  • PFS -0.02
  • Stochastic Oscillator
  • IBRX 1.19
  • PFS 37.84

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About PFS Provident Financial Services Inc

Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.

Share on Social Networks: